“High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study” (2022) Swiss Medical Weekly, 152(0102), p. w30122. doi:10.4414/SMW.2022.w30122.